Keywords : Amyloidosis
This report provides data on the therapeutic development for Amyloidosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Amyloidosis. 'Amyloidosis - Pipeline Review, H1 2012' is built using data and information sourced from Global Industries Direct’s proprietary databases, Firms /University websites, SEC filings, investor present...
More »
Search ReportLinker
The Largest Collection of Market Research Reports
» 1.2 Million Industry Reports
» 450,000 Company Profiles
» 850,000 Market Briefings
» 40,000 Country Guides
From +200,000 authoritative sources
This report provides data on the therapeutic development for Amyloidosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Amyloidosis. 'Amyloidosis - Pipeline Review, H1 2012' is built using data and information sourced from Global Industries Direct’s proprietary databases, Firms /University websites, SEC filings, investor presentations and featured press releases from firm /university sites and market -specific third party sources, put together by Global Industries Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope of the Research
- A snapshot of the global therapeutic scenario for Amyloidosis.
- A review of the Amyloidosis products under development by industry players and universities/research institutes based on information derived from industry player and market -specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Amyloidosis pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage new product development featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Amyloidosis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and take over s effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Amyloidosis pipeline depth and focus of Amyloidosis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and grow business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Global Pathology Industry
Table of Contents
Data table of Contents
Data table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global March kets Direct Report Coverage 9
Amyloidosis Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Amyloidosis 11
Amyloidosis Therapeutics under Development by Firms 13
Amyloidosis Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 17
Comparative Analysis 17
Mid Clinical Stage Products 18
Comparative Analysis 18
Early Clinical Stage Products 19
Comparative Analysis 19
Pre-Clinical Stage Products 20
Comparative Analysis 20
Amyloidosis Therapeutics – Products under Development by Firms 21
Amyloidosis Therapeutics – Products under Investigation by Universities/Institutes 22
Companies Involved in Amyloidosis Therapeutics Development 25
GlaxoSmithKline plc 25
Millennium Pharmaceuticals, Inc. 26
Pfizer Inc. 27
Alnylam Pharmaceuticals, Inc 28
ProteoTech, Inc. 29
Celtic Therapeutics Holdings L.P. 30
Amyloidosis – Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Combination Products 32
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 38
MLN9708 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Kiacta - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Systebryl - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Lenalidomide + Melphalan + Dexamethasone - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Revlimid + Dexamethasone + Endoxan - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
ALN-TTR01 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
ALN-TTR02 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Iododoxorubicin - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Vyndaqel - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Velcade + Melphalan + Dexamethasone - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Velcade + Dexamethasone + Melphalan + Stem Cell Transplantation - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 55
Revlimid + Dexamethasone + Cyclophosphamide - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Revlimid + Cyclophosphamide + Dexamethasone - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Filgrastim + Melphalan - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Dexamethasone + Pomalidomide - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Melphalan + Lenalidomide + Dexamethasone - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Bortezomib + Dexamethasone + Melphalan - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Bortezomib + Cyclophosphamide + Dexamethasone - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Filgrastim + Melphalan + Autologous Hematopoietic Stem Cell Transplantation - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Dexamethasone + Melphalan + Thalidomide + Filgrastim - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Revlimid - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Melphalan + Autologous Stem Cell Transplantation + Bortezomib + Dexamethasone - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Filgrastim + Melphalan + Cyclophosphamide + Dexamethasone + Thalidomide + Peripheral Blood Stem Cell Transplantation - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 74
Recombinant interferon alfa + Dexamethasone - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Filgrastim + Cyclophosphamide + Dexamethasone + Melphalan + Thalidomide - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 77
Interferon Alfa + Dexamethasone - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Lenalidomide + Melphalan + Dexamethasone - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 80
bortezomib + dexamethasone + melphalan - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 82
Filgrastim + Bortezomib + Melphalan + Autologous Hematopoietic Stem Cell Transplantation - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 84
filgrastim + recombinant interferon alfa + sargramostim + busulfan + cyclophosphamide + melphalan - Drug Profile 85
Product Description 85
Mechanism of Action 86
R&D Progress 86
Diflunisal - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Velcade + Adriamycin + Dexamethasone - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
Velcade + Cyclophosphamide + Dexamethasone - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Lenalidomide + Cyclophosphamide + Dexamethasone - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
Doxycycline + Tauroursodeoxycholic Acid - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Melphalan + Peripheral Blood Stem Cell Transplantation + G-CSF - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Filgrastim + Melphalan + Autologous Peripheral Blood Stem Cell Transplantation - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
GSK2315698 - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
High Dose Chemotherapy + Autologous Hematopoietic Cell Transplantation - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
Bortezomib + Dexamethasone + Melphalan - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
Vincristine + Doxorubicin + Dexamethasone + G-CSF + Melphalan + Peripheral Blood Stem Cell Transplantation - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 103
Amyloidosis Therapeutics – Drug Profile Updates 104
Amyloidosis Therapeutics – Discontinued Products 110
Amyloidosis Therapeutics - Dormant Products 111
Amyloidosis – Product Development Milestones 112
Featured News & Press Releases 112
February 15, 2012: FDA Accepts Pfizer’s New Drug Application For Tafamidis Meglumine To Treat Transthyretin Familial Amyloid Polyneuropathy 112
February 13, 2012: Powerful Myeloma Treatment Regimen Shows Promise For AL amyloidosis, Research Finds 112
January 06, 2012: Alnylam Files Clinical Trial Application For ALN-TTR02 For Treatment Of Transthyretin-Mediated Amyloidosis 113
November 21, 2011: Alnylam Presents Positive Preliminary Clinical Results For ALN-TTR01 114
November 15, 2011: Alnylam To Present Phase I Clinical Data At 8th International Symposium On Familial Amyloidotic Polyneuropathy 115
June 28, 2011: Alnylam Presents New Data From ALN-TTR Program At Peripheral Nerve Society Meeting 116
December 15, 2010: Celtic Therapeutics And Bellus Health Initiate Confirmatory Phase III Clinical Study For Kiacta 117
July 07, 2010: Alnylam Doses ATTR Patients In Phase I Clinical Study Of ALN-TTR01 118
July 07, 2010: Alnylam Doses ATTR Patients In Phase I Clinical Study Of ALN-TTR01 119
June 04, 2010: Millennium Presents Velcade Data On Relapsed Or Refractory Amyloidosis At American Society of Clinical Oncology Annual Meeting 119
Appendix 121
Methodology 121
Coverage 121
Secondary Research 121
Primary Research 121
Expert Panel Validation 121
Contact Us 122
Disclaimer 122
List of Tables
List of Tables
Number of Products Under Development for Amyloidosis, H1 2012 11
Products under Development for Amyloidosis – Comparative Analysis, H1 2012 12
Number of Products under Development by Firms, H1 2012 13
Number of Products under Investigation by Universities/Institutes, H1 2012 15
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 16
Comparative Analysis by Late Stage Development, H1 2012 17
Comparative Analysis by Mid Clinical Stage Development, H1 2012 18
Comparative Analysis by Early Clinical Stage Development, H1 2012 19
Comparative Analysis by Pre-Clinical Stage Development, H1 2012 20
Products under Development by Firms, H1 2012 21
Products under Investigation by Universities/Institutes, H1 2012 22
Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 23
Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 24
GlaxoSmithKline plc, H1 2012 25
Millennium Pharmaceuticals, Inc., H1 2012 26
Pfizer Inc., H1 2012 27
Alnylam Pharmaceuticals, Inc, H1 2012 28
ProteoTech, Inc., H1 2012 29
Celtic Therapeutics Holdings L.P., H1 2012 30
Assessment by Monotherapy Products, H1 2012 31
Assessment by Combination Products, H1 2012 32
Assessment by Stage and Route of Administration, H1 2012 34
Assessment by Stage and Molecule Type, H1 2012 37
Amyloidosis Therapeutics – Drug Profile Updates 104
Amyloidosis Therapeutics – Discontinued Products 110
Amyloidosis Therapeutics – Dormant Products 111
List of Figures
List of Figures
Number of Products under Development for Amyloidosis, H1 2012 11
Products under Development for Amyloidosis – Comparative Analysis, H1 2012 12
Products under Development by Firms, H1 2012 13
Products under Investigation by Universities/Institutes, H1 2012 14
Late Stage Products, H1 2012 17
Mid Clinical Stage Products, H1 2012 18
Early Clinical Stage Products, H1 2012 19
Pre-Clinical Stage Products, H1 2012 20
Assessment by Monotherapy Products, H1 2012 31
Assessment by Combination Products, H1 2012 32
Assessment by Route of Administration, H1 2012 33
Assessment by Stage and Route of Administration, H1 2012 34
Assessment by Molecule Type, H1 2012 35
Assessment by Stage and Molecule Type, H1 2012 36
